Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Wienecke

Neurological Surgery Oklahoma City, OK Medical Doctor

NPI 1669461000 CMS profile 211163

14100 Parkway Commons Dr Ste 100, Suite 100, Oklahoma City, OK 73134

Open in the dashboard

General payments

$40,034

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Wienecke of Oklahoma City, OK is reported in the CMS Open Payments database as having received $40,034 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $230 1
2024 General $65 3
2023 General $3,530 18
2022 General $3,981 13
2021 General $7,464 9
2020 General $22,278 12
2019 General $2,486 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Wienecke
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Robert Wienecke were reported at $230. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Robert Wienecke Neurological Surgery median Middle half National median
2019 $2,486 $582 $138–$3,006 $163
2020 $22,278 $294 $76–$2,174 $114
2021 $7,464 $387 $105–$2,432 $132
2022 $3,981 $542 $139–$2,989 $149
2023 $3,530 $534 $145–$2,697 $160
2024 $65 $574 $155–$3,046 $164
2025 $230 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alphatec Spine, Inc $34,011 14 payments
  2. Medtronic, Inc. $3,099 30 payments
  3. Integrity Implants Inc $2,382 13 payments
  4. Curiteva, Inc. $230 1 payment
  5. Medtronic USA, Inc. $167 11 payments
  6. Baxter Healthcare $45 2 payments
  7. Intrinsic Therapeutics $36 1 payment
  8. Ethicon US, LLC $36 1 payment
  9. Allergan Inc. $16 1 payment
  10. Arteriocyte Medical Systems, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $34,011 14 payments
  2. Travel and Lodging $3,779 13 payments
  3. Food and Beverage $2,200 47 payments
  4. Gift $44 1 payment
Products named General payments · program years 2019–2025
  1. Arsenal Degenerative $28,443 7 payments
  2. Arsenal Deformity $11,860 10 payments
  3. FlareHawk $2,333 11 payments
  4. CD HORIZON SPINAL SYSTEM $1,776 10 payments
  5. MAZOR X SYSTEM $1,234 16 payments
  6. ACTIVA Deep Brain Neurostimulation $138 9 payments
  7. FLOSEAL $45 2 payments
  8. ACTIVA Deep Brain Neurostimulation $38 2 payments
  9. Barricaid Annular Closure Device $36 1 payment
  10. CLYDESDALE PTC SPINAL SYSTEM $36 1 payment
  11. Other $96 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

418

Median for Neurosurgery: 83

Drug cost

$3,956

Median for Neurosurgery: $872

Branded share of claims

14.8%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 93 $719
Gabapentin Generic 62 $668
Oxycodone Hcl Generic 82 $662
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 46 $500
Baclofen Generic 14 $378
Methylprednisolone Generic 37 $220
Cyclobenzaprine Hcl Generic 21 $202
Pregabalin Generic 16 $198
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $171
Hydromorphone Hcl Generic 18 $137

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$298,876

Medicare's payments for the services billed

Medicare patients

407

Average age 72

Services billed

1,773

244 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Ischemic heart disease 34%
Diabetes 29%
Osteoporosis 26%
Chronic kidney disease 21%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record